Literature DB >> 15373712

Population-based survival from cancers of breast, cervix and ovary in women in Mumbai, India.

Balkrishna Bhika Yeole1, A Venkata Ramana Kumar, Arun Kurkure, Lizzy Sunny.   

Abstract

BACKGROUND: Breast, cervix and ovarian cancers contribute more than 45% of the total in women in Mumbai and survival proportions for these neoplasms are very high in most developed populations in the World. The authors here report and discuss the population-based survival for these cancers in Mumbai, India.
METHODS: Follow-up information on 4865 cancers of breast, cervix and ovary, registered in the Mumbai Population Based Cancer Registry for the period 1992-1994 was obtained by a variety of methods, including matching with death certificates from the Mumbai vital statistics registration system, postal/telephone enquiries, home visits and scrutiny of medical records. The survival for each case was determined as the duration between the date of diagnosis and date of death, date of loss to follow-up or the closing date of the study (December 31(st), 1999). Cumulative observed and relative survival was calculated by the Hakulinen Method. For comparison of results with other populations, age-standardized relative survival (ASRS) was calculated by directly standardizing age specific relative survival to the specific age distributions of the estimated global incidence of major cancers in 1985. The log rank test was used in univariate analysis to identify the potentially important prognostic variables. The variables showing statistical significance in univariate analysis were introduced stepwise into a Cox Regression model to identify the independent predictors of survival.
RESULTS: The 5-year relative survival rates were 46.2% for breast, 47.7% for the cervix and 25.4% for the ovary. Higher survival was observed for those younger than 35 years for all these three sites. For each, survival declined with advancing age. Single patients who remained unmarried had better survival. For all sites Muslims had a better and Christians a lower survival as compared to Hindus. Education did not appear to be of significance. Survival decreased rapidly with advancing clinical extent of disease for all sites. With localized cancer, 5-year rates ranged from 54.7% to 69.3%, for regional spread 20.4% to 41.6% and distant metastasis not a single site recorded more than 5%. On multivariate analysis, age and extent of disease emerged as independent predictors of survival for all the sites.
CONCLUSION: All the sites included in the study demonstrated moderate survival rates with significant variation. Comparison with other populations revealed lower survival rates as compared to developed countries, particularly for breast and ovary. In Indian populations survival proportions did not show much variation for these cancers. Early detection and treatment are clearly important factors to reduce the mortality from these cancers.

Entities:  

Mesh:

Year:  2004        PMID: 15373712

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  19 in total

1.  Incorporating EBO-HSIC with SVM for Gene Selection Associated with Cervical Cancer Classification.

Authors:  S Geeitha; M Thangamani
Journal:  J Med Syst       Date:  2018-10-06       Impact factor: 4.460

2.  Differences of Quality in End-of-Life Care across Settings: Results from the U.S. National Health and Aging Trends Study of Medicare Beneficiaries.

Authors:  Shuo Xu; Mangdong Liu; Oejin Shin; Vanessa Parker; Rosalba Hernandez
Journal:  J Palliat Med       Date:  2020-03-09       Impact factor: 2.947

3.  Ovarian masses: changing clinico histopathological trends.

Authors:  So Sharadha; T A Sridevi; T K Renukadevi; R Gowri; Debbarman Binayak; V Indra
Journal:  J Obstet Gynaecol India       Date:  2014-06-06

4.  Serum human telomerase reverse transcriptase: a novel biomarker for breast cancer diagnosis.

Authors:  Mahendar Porika; Radhika Tippani; Sekhar R Bollam; Sree Divya Panuganti; Christopher Thamidala; Sadanandam Abbagani
Journal:  Int J Clin Oncol       Date:  2011-04-28       Impact factor: 3.402

5.  Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer.

Authors:  Manizheh Sayyah-Melli; Gita Kashi Zonoozi; Shahryar Hashemzadeh; Ali Esfahani; Elaheh Ouladehsahebmadarek; Mehry Jafary Shobeiry; Parvin Mostafa Garabaghi; Azhough Ramin
Journal:  J Obstet Gynaecol India       Date:  2013-08-14

6.  Down-regulation of microRNA-135b inhibited growth of cervical cancer cells by targeting FOXO1.

Authors:  Yue Xu; Shuhua Zhao; Manhua Cui; Qiang Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Role of Neoadjuvant Chemotherapy (NACT) Followed by Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer.

Authors:  Sonia Batra; Himanshu Nayak; Kalpna S Dave
Journal:  J Obstet Gynaecol India       Date:  2012-03-07

8.  Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976-2005: an age-period-cohort analysis.

Authors:  P K Dhillon; B B Yeole; R Dikshit; A P Kurkure; F Bray
Journal:  Br J Cancer       Date:  2011-08-09       Impact factor: 7.640

Review 9.  Epidemiology of cervical cancer with special focus on India.

Authors:  Aswathy Sreedevi; Reshma Javed; Avani Dinesh
Journal:  Int J Womens Health       Date:  2015-04-16

10.  Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran.

Authors:  Abbas Rezaianzadeh; Janet Peacock; Daniel Reidpath; Abdolrasoul Talei; Seyed Vahid Hosseini; Davood Mehrabani
Journal:  BMC Cancer       Date:  2009-06-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.